- [Interview] David Jeon, CEO and founder of L-BASE, established the company in 2015
- Advancing a next-generation anticancer drug: CAGE-derived peptide-based treatment
- ‘LB217’ in development for non-small cell lung cancer: Anticipated to be effective with Tagrisso
- Non-cancer phase completed in Italy; IND application for phase 1 clinical trial in the UK planned for H2 2025

https://www.thebionews.net/news/articleView.html?idxno=7781